Ifebemtinib (hydrochloride)

Ifebemtinib (BI-853520) hydrochloride is an orally active and potent focal adhesion kinase (FAK) inhibitor (IC50 = 1 nM for recombinant FAK) . Ifebemtinib hydrochloride exhibits antiproliferative activity against cancer cells[1][2][3].

Product Specifications

Product Name Alternative

BI-853520 (hydrochloride) ; IN-10018 (hydrochloride)

UNSPSC

12352005

Target

FAK

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ifebemtinib-hydrochloride.html

Concentration

10mM

Purity

99.22

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(C1=C(F)C=C(NC2=NC=C(C(F)(F)F)C(OC3=CC=CC4=C3C(N(C4)C)=O)=N2)C(OC)=C1)NC5CCN(CC5)C.[H]Cl

Molecular Formula

C28H29ClF4N6O4

Molecular Weight

625.01

References & Citations

[1]Hirt UA, et al. Efficacy of the highly selective focal adhesion kinase inhibitor BI 853520 in adenocarcinoma xenograft models is linked to a mesenchymal tumor phenotype. Oncogenesis. 2018 Feb 23;7 (2) :21.|[2]Stefanie Tiede, et al. The FAK inhibitor BI 853520 exerts anti-tumor effects in breast cancer. Oncogenesis. 2018 Sep 20;7 (9) :73.|[3]Ulrich A Hirt, et al. Efficacy of the highly selective focal adhesion kinase inhibitor BI 853520 in adenocarcinoma xenograft models is linked to a mesenchymal tumor phenotype. Oncogenesis. 2018 Feb 23;7 (2) :21.